Atypical pituitary adenoma (APA) and pituitary carcinoma (PC) were defined according to immunohistochemical staining characteristics and presence of metastasis. Adenomas with atypical morphological features of invasive growth, increased number of mitoses, extensive nuclear staining for p53, and a Ki67 (MIB-1) proliferation index of 3% or more were classified as APAs. In surgical series, APAs were identified in 2.7-14.8% Treatment of aggressive pituitary tumors may be challenging. Temozolomide (TMZ) is a promising agent when conventional treatment methods fail. We present three patients with aggressive pituitary tumors with atypical morphology, who were resistant to conventional treatments and treated with TMZ. The first case had a somatotroph adenoma, the second a corticotroph adenoma, and the third a macroprolactinoma. We also reviewed the literature reporting TMZ efficacy in somatotroph, corticotroph and mammotroph tumors of the pituitary gland. TMZ with a schedule of 150-200 mg/m 2 for 5 days every 28 days was administered to all patients. Even though only the case of macroprolactinoma had a favorable response to TMZ treatment among our patients, both radiological and hormonal recurrence occurred 30 months after the cessation of TMZ treatment. TMZ treatment was then administered again. Cases of somatotroph and corticotroph adenomas had progressed under TMZ treatment and the patients were lost due to mass effect of the tumor. A review of the literature demonstrated 67.3%, 60% and 26.7% overall response rates to TMZ treatment in prolactinoma, corticotropinoma and somatostatinoma cases, respectively. There is still a need to define response criteria uniformly to TMZ treatment in aggressive pituitary tumors. The duration of response should be reported for reliable evaluation of results.
█ INTRODUCTION P ituitary adenomas (PAs) are relatively frequent tumors with an estimated prevalence of 80-90 per 100,000 and account for 15% of intracranial neoplasms (25, 55) . The large majority of pituitary adenomas are benign. However, aggressive, invasive or malignant tumors of the pituitary gland may develop and treatment of these tumors is quite challenging. A classification for pituitary adenomas was developed by World Health Organization (WHO) in 2004 (39) . The WHO classification suggested the prediction of potentially "aggressive adenomas" with histopathological features.
Treatment of aggressive pituitary tumors may be challenging. Temozolomide (TMZ) is a promising agent when conventional treatment methods fail. We present three patients with aggressive pituitary tumors with atypical morphology, who were resistant to conventional treatments and treated with TMZ. The first case had a somatotroph adenoma, the second a corticotroph adenoma, and the third a macroprolactinoma. We also reviewed the literature reporting TMZ efficacy in somatotroph, corticotroph and mammotroph tumors of the pituitary gland. TMZ with a schedule of 150-200 mg/m 2 for 5 days every 28 days was administered to all patients. Even though only the case of macroprolactinoma had a favorable response to TMZ treatment among our patients, both radiological and hormonal recurrence occurred 30 months after the cessation of TMZ treatment. TMZ treatment was then administered again. Cases of somatotroph and corticotroph adenomas had progressed under TMZ treatment and the patients were lost due to mass effect of the tumor. A review of the literature demonstrated 67.3%, 60% and 26.7% overall response rates to TMZ treatment in prolactinoma, corticotropinoma and somatostatinoma cases, respectively. There is still a need to define response criteria uniformly to TMZ treatment in aggressive pituitary tumors. The duration of response should be reported for reliable evaluation of results.
adenomas is different from both benign and malign adenomas and they can be considered as an intermediate form. APAs may not be aggressive tumors and also aggressive adenomas may not be APAs. However, atypical histopathology according to WHO criteria was suggested as an independent risk factor for aggressive tumor behavior (1).
PCs and aggressive/atypical adenomas are usually resistant to conventional treatments and have poor prognosis (33, 68, 76) . Conventional chemotherapeutic drugs do not have impact on survival and tumor recurrence in these tumors (33, 68) . Thus, PCs /APAs require additional treatment modalities when residual or recurrent tumors are resistant to classical treatment options.
Temozolomide (TMZ) is an orally administered, secondgeneration, alkylating chemotherapeutic drug capable of crossing the blood-brain barrier (5) . The principal mechanism responsible for the cytotoxicity of TMZ is the methylation of deoxyribonucleic acid (DNA) that results in strand breaks and cell death (42) . TMZ was shown to be a promising chemotherapeutic drug for salvage therapy of aggressive adenomas and PCs. In the last decade, TMZ treatment has been used in aggressive pituitary adenomas and carcinomas that were resistant to classical treatment options. Since the first case of aggressive pituitary adenoma was treated with TMZ, more than 100 cases of pituitary tumors including PCs and aggressive adenomas managed with TMZ have been reported (16, 79) . Even though these case reports and small series have shown that TMZ could be an alternative treatment option for PCs and aggressive adenomas, there is still a need for more experience in using this drug due to the heterogeneous and limited number of results among same pituitary tumor types. Experience with somatotropinomas is especially limited with only fourteen cases and not sufficient to create a general impression (6, 7, 12, 27, 43, 50, 72) .
We therefore present our experience with TMZ in the management of three aggressive pituitary adenomas, somatotroph, corticotroph and mammotroph tumors, refractory to conventional treatment strategies. In addition, we reviewed the literature reporting TMZ efficacy in these tumors.
█ CASE REPORTS Case 1
The first patient was a 55-year-old man who had an invasive growth hormone (GH)-secreting pituitary macroadenoma. He presented in September 2006 with headache, visual loss, perspiration, enlarged hands and feet. Physical examination demonstrated macroglossia, enlargement of hands and feet, prognathism, frontal bossing, mandibular enlargement and teeth separation. His pulse rate was 78 beats per minute and blood pressure was 150/90 mm Hg. On laboratory examination, the serum IGF-1 level was 691 ng/ml (normal range [N]; 94-284) and GH level was 2.7 mcg/L (N, 0-6.7 mcg/L). The GH level was not suppressed (> 1.9 mcg/L) after a 75-gram oral glucose load. Pituitary magnetic resonance imaging (MRI) revealed a giant macroadenoma with suprasellar extension and invasion of the right sphenoid sinus. Figure 1A , B). He died because of local tumor effects.
Case 2
A 29-year-old man presented with loss of libido and malaise. On physical examination, his blood pressure was 130/90 mm Hg and pulse rate was 84 beats per minute. He had abdominal purple blue wide striae, proximal muscle weakness and facial plethora. Laboratory investigations showed elevated urinary free cortisol level of 138 mcg/24 hrs (normal range [N]; 10-80 mcg/24 hrs). Cortisol suppression was not obtained after overnight 1 mg and subsequent 2 mg (classical two days) dexamethasone suppression tests (30.2 mcg/dl and 26.6 mcg/dl respectively). Plasma adrenocorticotropic hormone (ACTH) level was normal (32 pg/ml, N;7.2-63.3 pg/ml). Pituitary MRI revealed a macroadenoma 24 mm in diameter, invading the left cavernous sinus and internal carotid artery (ICA) (Figure 2A-C) . The visual field was normal. Adrenal computed tomography (CT) showed normal adrenal glands. These findings indicated ACTH-dependent Cushing's disease. The patient underwent TN/TS pituitary adenomectomy. Histopathological examination showed a 99% ACTH-positive adenoma with 10% Ki67 proliferation index and extensive p53 staining.
Postsurgical pituitary MRI revealed a residual mass adjacent to the left ICA. Stereotactic radiosurgery (25Gy) (CyberKnife, Accuray, Sunnyvale, California, USA) was used for the patient due to the presence of a residual tumor on pituitary MRI and left eyelid ptosis. After this treatment, the ptosis regressed dramatically. Four months later, Pasireotide (600 μg, subcutaneously, twice daily) treatment was started. The only side effect of pasireotide was mild hyperglycemia that responded to oral antidiabetic treatment. At the second month of pasireotide therapy, right eyelid ptosis occurred. Pituitary MRI showed that the residual mass on the left side had totally disappeared but there was a new macroadenoma located on the right side of the adenohypophysis (Figure 2A-C) . Radiotherapy was not planned again because of the short time period after the first session of Cyber Knife and possible side effects on the optic chiasm. The patient underwent a second TN/TS adenomectomy. Immunohistochemistry revealed extensive p53 staining (>50%) and 15% Ki67 proliferation index. MGMT staining was not available.
Although no mass was observed on pituitary MRI (Figure 2A -C), the postoperative clinical picture of patent were consistent with residual disease and the level of urinary free cortisol was 968 nmol/day (N; 38-208). Temozolomide treatment was started at a dose of 200 mg/m 2 /day, for 5 days every 28 days. After three cycles of TMZ, response evaluation showed progressive disease. Urinary free cortisol level was 8658 nmol/ day (N; 38-208) and ACTH level was elevated to 197 pg/ml (N; 7.2-63.3). Pituitary MRI revealed a recurrent mass at the left side of the pituitary. TMZ was no longer continued because of unresponsiveness. The only side effect of TMZ was mild nausea. Left eyelid ptosis relapsed and CyberKnife treatment was applied again. The ptosis regressed after radiosurgery, but hormonal and radiological evidence of disease persisted. The patient was lost due to massive pulmonary thromboembolism.
Case 3
A 65-year-old woman presented with headache and a previous history of macroprolactinoma in November 2011. On physical examination, her blood pressure was 120/75 mm Hg and the pulse rate was 70 beats per minute. She had right eyelid ptosis and visual disturbances. Computerized visual field test revealed bitemporal superior quadranopia. 
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A B C sion (9-100%) and tumor recurrence occurred at 15 th month of TMZ treatment. A somatotroph PC with high MGMT expression (90%) was reported to progress under TMZ treatment. These data may reflect the impact of lower MGMT expression as a good prognostic marker for TMZ response in aggressive macrosomatostatinomas. All other reports of somatotroph adenomas revealed unresponsiveness to TMZ therapy (6, 12, 27, 40, 43, 50, 72) . Previously, low MGMT immunoexpression was demonstrated in a majority of somatotroph tumors (83.3%), including tumors with high Ki-67 labeling index (80) . However, two of the reported MGMT negative somatotroph adenomas were non-responders, raising the concerns about significance of MGMT status (7, 12, 27) .
In our case with aggressive somatotroph adenoma, tumor size and IGF-1 level were stable until the sixth cycle of TMZ therapy, but rapid progression occurred thereafter. Consequently, according to the current review of the literature including the present case, the response rate to TMZ among aggressive somatotroph adenomas was 26.7% (4/15 of cases).
Corticotroph adenomas are more aggressive tumors compared to other pituitary neoplasms (23, 26) . The five-year mortality rate has been reported as high as 50% for untreated patients (59) . Remission after surgical therapy is achieved in 65-90% of ACTH-secreting pituitary microadenomas and as low as 25-30% of macroadenomas in some series (9, 10, 19) . Relapse rate in ten years is also higher for macroadenomas (%12-36 vs. %10-20) (9) . When residual or recurrent disease is observed; radiotherapy/radiosurgery, medical treatment (somatostatin receptor analogues) and bilateral adrenalectomy are the treatment options. A subgroup of corticotroph tumors is resistant to all conventional therapies. Approximately 50% of patients cannot be cured with repeated surgery (64) . When the MGMT status of invasive and recurrent corticotroph adenomas was investigated, low immunoexpression was demonstrated in 60% and 86% of these tumors, respectively (66) . Nelson syndrome and Crooke cell macroadenomas were also reported to have low MGMT expression in most cases (66, 71) . According to these limited data, TMZ has been MRI were observed. The cabergoline dose was increased to 7 mg/week but no response was seen. TMZ was restarted at 200 mg/m 2 /day, for 5 days every 28 days. After three cycles of TMZ, response evaluation revealed tumor progression on pituitary MRI and increased PRL level (3700 ng/ml) ( Figure 3A -C). Surgery was recommended but the patient did not accept any medical or surgical treatment.
█ DISCUSSION
Several cases with aggressive pituitary adenoma or carcinoma treated with TMZ have been published during the last decade with an estimated 60-70% response rate (13, 60) . Favorable results were usually reported in macroprolactinomas and adrenocorticotropinomas (12, 13, 30, 60, 73) . Low expression of MGMT, which is a DNA repair protein and reverses methylation caused by TMZ, was suggested as a predictor of good response to TMZ (35) .
Management of macrosomatotropinoma may be more challenging, because 40-60% of them cannot be controlled with surgery, and recurrence of tumor initially thought to be cured by surgery was reported in approximately 10% of cases (8, 44) . However, tumor growth after radiotherapy is seen in less than 1% of patients (8) . Experience with TMZ in somatotroph adenomas is limited due to low frequency of resistance to standard treatments or reporting bias. We found fourteen somatotroph tumors treated with TMZ in the literature (Table I) (6, 7, 12, 27, 43, 50, 72) . Bengtsson et al. reported two complete and two partial responses to TMZ among six somatotroph tumors (outcome data was available for five patients) including three aggressive adenomas and three PCs (7). Partial response was seen in two aggressive tumors (one had a shift from PRL to GH secretion) and complete response with normal IGF-1 levels in two carcinomas (one had a shift from PRL to GH secretion). Efficacy of TMZ was also reported in PCs with no relapse at 48 and 91 months of therapy. One of those aggressive adenomas and both of PCs had low (9%) MGMT immunoexpression. The remaining adenoma with partial response had heterogeneous MGMT immunoexpres- 
A B C
described as dopamine agonist resistant tumors. In most cases, resistance to dopamine agonists develop due to patient incompliance or estrogen replacement (48). Moreover, malignant transformation of the tumor is also reported (31) . In cabergoline resistant tumors, surgery generally fails to normalize PRL. TMZ was shown to have efficacy on aggressive macroprolactinomas and is recommended for the treatment of malignant prolactinoma in the recent clinical practice guideline of the Endocrine Society (45) . In the literature, according to our best knowledge, 45 aggressive macroprolactinomas treated with TMZ have been reported (Table III) . Only three patients (6.5%) achieved complete response and all of them had negative/low MGMT immunoexpression (7, 22, 24, 29) . Excitingly, one patient was reported to be in remission at 91 months follow-up (7). Twenty-eight patients (60.8%) were partial responders. Four patients with negative MGMT immunoexpression were resistant to TMZ (16, 29, 40, 61 Depending on the previous case reports, the sensitivity and specificity of the MGMT status in predicting TMZ responsiveness of corticotroph tumors was reported to be 80% and 70% respectively (2).
Forty-nine cases of corticotroph tumors treated with TMZ have been reported in the literature so far (Table II) . Among them, 25 PR and 5 CR were noted (Table II) . Consequently, according to the current review of the literature, including the present case, the frequency of complete and partial response to TMZ among aggressive corticotroph tumors was 10% and 50%, respectively. The duration of response was unavailable or quite limited for most cases. The longest lasting effect of TMZ in a corticotroph tumor was 30 months after stopping therapy (12) . Five patients had complete response under TMZ treatment (16, 29, 41, 71) . One of them had an MGMT positive tumor and others had negative or low MGMT immunoexpression. Eight partial responders were reported to have low or negative MGMT immunoexpression (Table II) . Three patients were reported to be non-responders despite negative to low MGMT staining. Unfortunately, MGMT status was not available in the remaining twelve patients, including the present case (Table II) . , 5 NR out of 13 subjects but noted that recurrence occurred in 6 (46%) patients after an effective response. As mentioned above, a patient who was accepted as a responder may be a non-responder according to different criteria or vice versa. Also, it is not clear whether or not patients with stable tumors should be accepted as responders. A recent analysis of Italian patients who were treated with TMZ revealed disease control in 25/31 (80.6 %) of cases when stable tumors were included. However, reduction of tumor size or hormonal normalization was achieved only in 35.5% and 28.6% of the patients, respectively (40) . Moreover, the reported response rates might have been overestimated due to more frequent reporting of responders than non-responders as well. Therefore, an uniform description of response criteria is needed for reliable evaluation of TMZ responsiveness.
Approximately 90% of prolactinomas are responsive to dopamine agonists (49). Aggressive macroprolactinomas are
MGMT immunoexpression status is the most commonly studied factor affecting TMZ responsiveness. Immunohistochemistry is the preferred method for detection of MGMT status in pituitary tumors (43 (17) . Unfortunately clinical data about these potential methods is not available yet. Alternative treatment options for TMZ resistant tumors include TMZ-pasireotide and TMZ-capecitabine combinations (16) . Successful treatment of aggressive Cushing Disease with the CAPTEM protocol (Capecitabine and TMZ combination) was reported in case reports and a recent small case series (61, 75) . Target of rapamycin inhibitor (everolimus), and targeted therapies (anti-vascular endothelial growth factor, epidermal growth factor receptor), were also reported on a case report basis (37, 41, 56) .
█ CONCLUSION
Approximately 50% of aggressive pituitary adenomas and carcinomas are responsive to TMZ. However, uniformly defined response criteria and relevant durations of response are still lacking. Clinical trials are also needed to identify treatment regimens for TMZ resistant pituitary tumors.
